P/E ratio for Veracyte (VCYT)
P/E ratio as of May 2024 (TTM): -50.9
According to Veracyte's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -50.875. At the end of 2022 the company had a P/E ratio of -47.5.
P/E ratio history for Veracyte from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -47.5 | 31.32% |
| 2021 | -36.1 | -49.78% |
| 2020 | -72.0 | -30.4% |
| 2019 | -103 | 434.3% |
| 2018 | -19.4 | 169.71% |
| 2017 | -7.18 | 1.98% |
| 2016 | -7.04 | 27.05% |
| 2015 | -5.54 | -22.03% |
| 2014 | -7.10 | -18.53% |
| 2013 | -8.72 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Exact Sciences EXAS | -39.1 | -23.05% | 🇺🇸 USA |
 Myriad Genetics MYGN | -6.40 | -87.41% | 🇺🇸 USA |
 Biocept
BIOC | -0.0085 | -99.98% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.